Effects of ATF-SAP on tumor growth in a subcutaneous xenograft bladder cancer mouse model. (A) Schematic representation of the experimental design. RT112 bladder cancer cells were subcutaneously injected in 7-week-old nude female mice. Tumor bearing mice were randomized into 2 experimental groups and treated respectively with PBS or ATF-SAP (0.5 mg/Kg) via intravenous injection every 5 days after tumor implantation. (B) Quantitative analysis of growing tumor volume in mice are shown as mean ± SD from respectively n = 6 mice per condition. (C) The mean weight of mice from each treatment group is shown as percentage from initial. (D) Kaplan–Meyer plot of animal survival with median survival time listed in the table. Results from a Mantel–Cox two-sided log-rank test are shown when statistically significant (**p < 0.01) for ATF-SAP 0.5 mg/kg (red; hazard ratio, 19.2; 95% CI, 2.2–165.8) versus PBS in mice bearing subcutaneous RT112 tumor.